Figure 2.
In vitro characterization of anti-BAFF-R afucosylated Ab, H90-AF. (A) Proportions of G0 and G1 core-fucosylated chains derived from H90-5 and H90-AF. The percentage of fucosylation of the oligosaccharide chains from each species of Ab is plotted and compared. (B) Deconvoluted mass spectra of H90-AF. Assigned glycoforms and observed mass are annotated on detected peaks. (C) ADCC assays of H90-5 and H90-AF against RL target cells with NK-92MI-CD16a effector cells at an E:T ratio of 5:1. Rituximab served as a positive control and an irrelevant IgG1 was the negative control. (D) ADCC assays of H90-5 and H90-AF against Jeko-1, Nalm-6, and Z138 target cells with NK cells from PBMC as effector cells at an E:T ratio of 10:1. Experiments were conducted in triplicate.

In vitro characterization of anti-BAFF-R afucosylated Ab, H90-AF. (A) Proportions of G0 and G1 core-fucosylated chains derived from H90-5 and H90-AF. The percentage of fucosylation of the oligosaccharide chains from each species of Ab is plotted and compared. (B) Deconvoluted mass spectra of H90-AF. Assigned glycoforms and observed mass are annotated on detected peaks. (C) ADCC assays of H90-5 and H90-AF against RL target cells with NK-92MI-CD16a effector cells at an E:T ratio of 5:1. Rituximab served as a positive control and an irrelevant IgG1 was the negative control. (D) ADCC assays of H90-5 and H90-AF against Jeko-1, Nalm-6, and Z138 target cells with NK cells from PBMC as effector cells at an E:T ratio of 10:1. Experiments were conducted in triplicate.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal